LAG-3 Antibody (17B4)

Images

 
Flow Cytometry: LAG-3 Antibody (17B4) [NBP1-97657] - Analysis using the FITC conjugate of NBP1-97657. Tumor infiltrating lymphocytes (TILs) express LAG-3 (detected using LAG-3 (human), mAb (17B4).
Flow Cytometry: LAG-3 Antibody (17B4) [NBP1-97657] - Analysis using the FITC conjugate of NBP1-97657. LAG-3 staining in resting and PHA activated lymphocytes. Image submitted by a verified customer review.
Western Blot: LAG-3 Antibody (17B4) [NBP1-97657] - Lane 1: MW marker. Lane 2: LAG-3 (human):Fc (human).
Flow Cytometry: LAG-3 Antibody (17B4) [NBP1-97657] - Analysis using the FITC conjugate of NBP1-97657. Staining of LAG-3 on CD4+ and CD8+ subpopulations of tumour infiltrating lymphocytes (TILs) detected with LAG-3 ...read more
Immunohistochemistry-Paraffin: LAG-3 Antibody (17B4) [NBP1-97657] - LAG-3 in human tonsil tissue sample. Image submitted by a verified customer review.
Flow Cytometry: LAG-3 Antibody (17B4) [NBP1-97657] - Analysis using the FITC conjugate of NBP1-97657. LAG-3 expression on activated human peripheral blood mononuclear cells (PBMC) detected with LAG-3 (human), mAb (17B4) ...read more
Flow Cytometry: LAG-3 Antibody (17B4) [NBP1-97657] - Analysis using the FITC conjugate of NBP1-97657. Method: LAG-3 (human), mAb (17B4) (FITC) (10 ug/mL) (is preincubated with a specific peptide epitope (208b) or a ...read more

Product Details

Summary
Reactivity Hu, PmSpecies Glossary
Applications WB, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, B/N
Clone
17B4
Clonality
Monoclonal
Host
Mouse
Conjugate
Unconjugated
Concentration
1.0 mg/ml

Order Details

LAG-3 Antibody (17B4) Summary

Immunogen
This LAG-3 Antibody (17B4) was prepared from synthetic peptide corresponding to 30 aa (GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY) from the first N-terminal D1 domain of human LAG-3 (lymphocyte activation gene-3).
Specificity
LAG-3 Antibody (17B4) recognizes the 30 aa extra-loop of the first N-terminal D1 domain of human LAG-3.
Isotype
IgG1
Clonality
Monoclonal
Host
Mouse
Gene
LAG3
Purity
Protein A or G purified
Innovator's Reward
Test in a species/application not listed above to receive a full credit towards a future purchase.

Applications/Dilutions

Dilutions
  • Block/Neutralize
  • Flow Cytometry
  • Immunocytochemistry/Immunofluorescence 1:10 - 1:500
  • Immunohistochemistry 1:10 - 1:500
  • Immunohistochemistry-Frozen 1:150
  • Immunohistochemistry-Paraffin
  • Immunoprecipitation 10 ug/mL
  • Western Blot 5 ug/mL
Application Notes
Blocking/neutralizing application reported in scientific literature (PMID: 29671649, PMID: 28935468)
Theoretical MW
57.5 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Reviewed Applications
Read 2 Reviews rated 4.5
using
NBP1-97657 in the following applications:

Publications
Read Publications using
NBP1-97657 in the following applications:

  • 1 publication
  • IHC
    2 publications

Reactivity Notes

Primate reactivity reported in scientific literature (PMID: 32284611).

Packaging, Storage & Formulations

Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Buffer
PBS, 10% glycerol
Preservative
0.02% Sodium Azide
Concentration
1.0 mg/ml
Purity
Protein A or G purified

Alternate Names for LAG-3 Antibody (17B4)

  • 17b4 lag3
  • 17b4 neutralizing
  • 17b4
  • anti human lag3
  • Anti-LAG-3 Antibody
  • CD223 Antibody
  • CD223 Antigen Antibody
  • CD223 antigen
  • CD223
  • Human LAG3 Antibody
  • Human LAG-3 Antibody
  • LAG-3 17b4
  • LAG-3 blocking
  • LAG3
  • LAG-3
  • lymphocyte activating 3
  • lymphocyte activation gene 3 protein
  • lymphocyte-activation gene 3
  • Secreted lymphocyte activation gene 3 protein
  • sLAG-3

Background

Lymphocyte activation gene-3 (LAG-3), also referred to as CD233, is a type I transmembrane protein with a theoretical molecular weight of 70 kDa that is a member of the immunoglobulin superfamily (IgSF) (1, 2). Human LAG-3 cDNA encodes 525 amino acids (aa) that includes a 28 aa signal sequence, a 422 aa extracellular domain (ECD) with four Ig-like domains (D1-D4), a transmembrane region and a highly charged cytoplasmic region. Within the ECD, human LAG-3 shares 70%, 67%, 76%, and 73% aa sequence identity with mouse, rat, porcine, and bovine LAG-3, respectively. The extracellular region of LAG-3 and the CD4 co-receptor share ~20% aa sequence homology but are structurally similar and both bind to major histocompatibility complex class II (MHCII) on antigen-presenting cells (APCs), although LAG-3 has much higher affinity (1, 3). LAG-3 is highly expressed in the lymph node, spleen, ovary, and appendix while expressed at a lower level in a variety of other tissues. More specifically, LAG-3 is expressed on activated CD4+ and CD8+ T cells, natural killer T (NKT) cells, natural killer (NK) cells, plasmacytoid dendritic cells (pDCs), and regulatory T cells (Tregs), but not on naive, or resting, T cells (1, 3).

As mentioned above, LAG-3 binds to MHCII and this occurs via a proline-rich amino acid loop in D1 (1, 3). Another unique feature of LAG-3 is the longer connecting peptide region between the D4 and the transmembrane, which is acted upon and cleaved by metalloproteinases a disintegrin and metallopeptidase domain (ADAM) 10 and ADAM17 to generate a soluble 54 kDa form of LAG-3 (sLAG-3) (1, 3). The interaction of LAG-3 with MHCII prevents the MHC molecule from binding to a T-cell receptor (TCR) or CD4, thereby functioning in an inhibitory role and suppressing the TCR signal (4). When LAG-3 crosslinks with the TCR/CD3 complex, it causes reduced T-cell proliferation and cytokine secretion (4). This negative regulation is important in controlling autoimmunity as one study found Lag3-/- NOD (non-obese diabetic) mice had accelerated diabetes onset and increased T-cell infiltration into islet cells (5). On the other hand, besides being a negative regulator of T-cells, LAG-3 binding to MHCII molecules on APCs induces dendritic cell maturation and cytokine secretion by monocytes (5, 6). In addition to MHCII, other reported ligands for LAG-3 includes fibrinogen-like protein 1 (FGL1), liver endothelial cell lectin (lSECtin), galectin-3 (Gal-3), and alpha-synuclein fibrils (1). Gal-3, for instance, is expressed on stromal cells and CD8+ T-cells in the tumor microenvironment and the interaction with LAG-3 was shown to be crucial for the suppression of secreted cytokine IFN-gamma and may control anti-tumor immune responses (1, 5). Interestingly, a mouse model of Parkinson's disease revealed LAG-3 binding to alpha-synuclein fibrils in the central nervous system, contributing to its pathogenesis (1, 5).

Recent cancer immunotherapeutic approaches have focused on inhibitory receptors such as LAG-3 to revive expression of cytotoxic T-cells to attack tumors (6). LAG-3 has been shown to be co-expressed and have synergy with another immune-checkpoint molecule called programmed-death 1 (PD-1) (1, 4, 5, 6). In a mouse model of colon adenocarcinoma LAG3 blockade alone was largely ineffective, however co-blockade of LAG-3 and PD-1 limited tumor growth and resulted in tumor clearance in 80% of mice, compared to 40% with PD-1 blockade alone (5). Additionally, in a model of fibrosarcoma the LAG-3/PD-1 duel blockade increased survival and the percentage of tumor-free mice (5). Analysis of a variety of human tumor samples (e.g. melanoma, colon cancer, head and neck squamous cell carcinoma) also suggest that LAG3 alone and combinatorial treatment with PD-1 may be a good target for treatment (1, 3-6). To date there are over 10 different agents targeting LAG-3 in clinical trials for cancer either as an anti-LAG-3 blocking antibody monotherapy or as a combination antagonist bispecific antibody, primarily with PD-1 (1, 3-6).

Alternative names for LAG-3 includes 17b4 lag3, 17b4 neutralizing, 17b4, CD223, FDC, LAG-3 17b4, LAG-3 blocking, and LAG3.

References

1. Maruhashi, T., Sugiura, D., Okazaki, I. M., & Okazaki, T. (2020). LAG-3: from molecular functions to clinical applications. Journal for Immunotherapy of Cancer, 8(2), e001014. https://doi.org/10.1136/jitc-2020-001014

2. Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., & Hercend, T. (1990). LAG-3, a novel lymphocyte activation gene closely related to CD4. The Journal of experimental medicine, 171(5), 1393-1405. https://doi.org/10.1084/jem.171.5.1393

3. Ruffo, E., Wu, R. C., Bruno, T. C., Workman, C. J., & Vignali, D. (2019). Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. Seminars in immunology, 42, 101305. https://doi.org/10.1016/j.smim.2019.101305

4. Long, L., Zhang, X., Chen, F., Pan, Q., Phiphatwatchara, P., Zeng, Y., & Chen, H. (2018). The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes & cancer, 9(5-6), 176-189.

5. Andrews, L. P., Marciscano, A. E., Drake, C. G., & Vignali, D. A. (2017). LAG3 (CD223) as a cancer immunotherapy target. Immunological reviews, 276(1), 80-96. https://doi.org/10.1111/imr.12519

6. Goldberg, M. V., & Drake, C. G. (2011). LAG-3 in Cancer Immunotherapy. Current topics in microbiology and immunology, 344, 269-278. https://doi.org/10.1007/82_2010_114

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Customers Who Viewed This Item Also Viewed...

7268-CT
Species: Hu
Applications: BA
NB100-524
Species: Hu, Mu
Applications: Flow-IC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
NBP2-67605
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-P, IP, WB
NBP2-79843
Species: Hu
Applications: CyTOF-ready, ELISA, Flow, ICC/IF, IHC, IHC-P, PA, WB
NBP1-19371
Species: Ca, Hu, Mu, Po, Rb, Rt
Applications: Dual ISH-IHC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, Simple Western, WB
NBP2-29460
Species: Pm, Pm-Cm, Hu, Pm, RM
Applications: Flow, ICC/IF, IHC, IHC-P
796-IC
Species: Mu
Applications: BA
AF123
Species: Hu
Applications: Block, ICC, WB
6507-IL/CF
Species: Hu
Applications: BA
NBP1-97657
Species: Hu, Pm
Applications: B/N, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
NBP1-49045
Species: Mu, Rt
Applications: Cell Depl, CyTOF-ready, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, InhibTFunc
DDX0131P-100
Species: Hu
Applications: Flow, Func, ICC/IF, IHC, IHC-Fr, IHC-P
NB200-540
Species: Ec, Mu
Applications: CyTOF-ready, Flow-IC, Flow, IA, ICC/IF, IHC, IHC-Fr, IHC-P, IP
211-TBB/CF
Species: Hu
Applications: BA
AF470
Species: Mu
Applications: IHC, Neut, WB
NBP2-67569
Species: Hu, Mu, Rt
Applications: Flow, ICC/IF, IHC, IHC-P, WB
NB100-77417
Species: Hu, Mu, Rt
Applications: CyTOF-ready, Flow, Func, ICC/IF, IHC, IHC-Fr, IHC-P, IP, In vitro, In vivo, WB

Publications for LAG-3 Antibody (NBP1-97657)(10)

We have publications tested in 2 confirmed species: Human, Primate.

We have publications tested in 2 applications: Flow, IHC.


Filter By Application
Flow
(1)
IHC
(2)
All Applications
Filter By Species
Human
(4)
Primate
(1)
All Species
Showing Publications 1 - 10 of 10.
Publications using NBP1-97657 Applications Species
El Halabi L, Adam J, Gravelle P et al. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma Clinical Lymphoma Myeloma and Leukemia Nov 1 2020 [PMID: 33277223] (IHC, Human)

Details:
Immunohistochemical analysis of biopsies from patients with classic Hodgkins lymphoma.
IHC Human
Dummer R, Lebbe C, Atkinson V et al. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i Nat Med Oct 1 2020 [PMID: 33020648]
Harper J, Gordon S, Chan C et Al. CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption Nat Med. [PMID: 32284611] (Flow, Primate) Flow Primate
Pericart S, Tosolini M, Gravelle P et al. Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining Cancers (Basel) 2018 Oct 31 [PMID: 30384489] (IHC, Human)

Details:
Citation using the FITC form of this antibody.
IHC Human
Wang J, Ti Y, Wang Y et al. LAG-3 Represents a Marker of CD4+ T Cells with Regulatory Activity in Patients with Bone Fracture. Immunol. Invest. Apr 19 2018 [PMID: 29671649] (Human) Human
Ma QY, Huang DY, Zhang HJ et al. Function and regulation of LAG3 on CD4(+)CD25(-) T cells in non-small cell lung cancer Exp. Cell Res. 2017 Sep 19 [PMID: 28935468] (Human) Human
Macon-Lemaitre L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology May 31 2005 [PMID: 15885122]

Details:
Citation using the FITC format of this antibody.
Di Carlo E, Cappello P, Sorrentino C et al. Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway. J Pathol. 2005 Jan. [PMID: 15586367]
Huard B, Gaulard P, Faure F et al. Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics. 1994 [PMID: 7506235]
Baixeras E, Huard B, Miossec C et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med. 1992 Aug. [PMID: 1380059]

Reviews for LAG-3 Antibody (NBP1-97657) (2) 4.52

Average Rating: 4.5
(Based on 2 reviews)
We have 2 reviews tested in 1 species: Human.

Reviews using NBP1-97657:
Filter by Applications
IHC-P
(1)
All Applications
Filter by Species
Human
(2)
All Species
Images Ratings Applications Species Date Details
 LAG-3 NBP1-97657
Enlarge
4
reviewed by:
Verified Customer
Human 03/07/2020
View

Summary

Sample Testedhuman tonsil
SpeciesHuman
LotN/A
Immunohistochemistry-Paraffin LAG-3 NBP1-97657
Enlarge
5
reviewed by:
Verified Customer
IHC-P Human 01/23/2018
View

Summary

ApplicationImmunohistochemistry-Paraffin
Sample TestedTonsil
SpeciesHuman
Lot02011620

Product General Protocols

Video Protocols

WB Video Protocol
ICC/IF Video Protocol

FAQs for LAG-3 Antibody (NBP1-97657). (Showing 1 - 3 of 3 FAQs).

  1. What is the concentration of your biotin conjugated LAG-3 antibody?
    • We actually do not determine the concentration of our conjugated antibodies but they are usually 80-100% the concentration of the base product, so the concentration should be at least 0.8 mg/ml.
  2. While using NBP1-97657AF750 in TMA with 2 other antibodies for CD163 & CD44, we are having an issue with background "swirls" that we have pinned down to what we think is the antibody leaching off of the stained tissue over time. It seems to be in a swirl, around the tissue, after several washes and then mounting. It seems like it is not staying put. The staining is specific though.  I’m inclined to think that this may have to do with the fluorophore itself not the antibody. Could you make suggestions as to what might be happening?
    • F/P ratios and concentration for the antibody you ordered, NBP1-97657AF750 (lot 012220), are:  F/P 7.356, 0.72mg/ml.  Dilution for WB at 5ug/ml is 1:200, so for IHC I would use 20ug/ml, or suggested 1ug 1:150 (~7ug/ml) for the conjugated antibody. For this AF750 fluorophore, we release conjugated with F/P between 3 and 13. And yes, the starting ratios are the same for all AF750 conjugates and they were established experimentally. I have looked at all these 3 antibodies, the data for unconjugated forms as these have the most validation, and it looks that both CD163 and LAG-3 are both weaker than the CD44 ab (require more antibody to be used), and the targets are also less abundant. When the targets are less abundant, using direct conjugates is usually not recommended as you do not get signal amplification as with the secondary antibody. Unluckily, these two antibodies also had lower F/P ratios than the CD44 antibody, for example. At this point my best guess is that the signal intensity for  CD163 and LAG-3 is so weak that it lets you see the "swirl" from the stronger CD44 signal. So, this may not be the best fluorophore (AF750 has moderate brightness (3 out of 5). For NIR, Dylight 750 might be better (4 out of 5) for your set up. 
  3. While using NBP1-97657AF750 in TMA with 2 other antibodies for CD163 & CD44, we are having an issue with background "swirls" that we have pinned down to what we think is the antibody leaching off of the stained tissue over time. It seems to be in a swirl, around the tissue, after several washes and then mounting. It seems like it is not staying put. The staining is specific though.  I’m inclined to think that this may have to do with the fluorophore itself not the antibody. Could you make suggestions as to what might be happening?
    • F/P ratios and concentration for the antibody you ordered, NBP1-97657AF750 (lot 012220), are:  F/P 7.356, 0.72mg/ml.  Dilution for WB at 5ug/ml is 1:200, so for IHC I would use 20ug/ml, or suggested 1ug 1:150 (~7ug/ml) for the conjugated antibody. For this AF750 fluorophore, we release conjugated with F/P between 3 and 13. And yes, the starting ratios are the same for all AF750 conjugates and they were established experimentally. I have looked at all these 3 antibodies, the data for unconjugated forms as these have the most validation, and it looks that both CD163 and LAG-3 are both weaker than the CD44 ab (require more antibody to be used), and the targets are also less abundant. When the targets are less abundant, using direct conjugates is usually not recommended as you do not get signal amplification as with the secondary antibody. Unluckily, these two antibodies also had lower F/P ratios than the CD44 antibody, for example. At this point my best guess is that the signal intensity for  CD163 and LAG-3 is so weak that it lets you see the "swirl" from the stronger CD44 signal. So, this may not be the best fluorophore (AF750 has moderate brightness (3 out of 5). For NIR, Dylight 750 might be better (4 out of 5) for your set up. 

Secondary Antibodies

 

Isotype Controls

Other Available Formats

Alexa Fluor 350 NBP1-97657AF350
Alexa Fluor 405 NBP1-97657AF405
Alexa Fluor 488 NBP1-97657AF488
Alexa Fluor 532 NBP1-97657AF532
Alexa Fluor 594 NBP1-97657AF594
Alexa Fluor 647 NBP1-97657AF647
Alexa Fluor 700 NBP1-97657AF700
Alexa Fluor 750 NBP1-97657AF750
Allophycocyanin NBP1-97657APC
Allophycocyanin/Cy7 NBP1-97657APCCY7
Biotin NBP1-97657B
DyLight 350 NBP1-97657UV
DyLight 405 NBP1-97657V
DyLight 488 NBP1-97657G
DyLight 550 NBP1-97657R
DyLight 594 NBP1-97657DL594
DyLight 650 NBP1-97657C
DyLight 680 NBP1-97657FR
DyLight 755 NBP1-97657IR
FITC NBP1-97657F
HRP NBP1-97657H
Janelia Fluor 549 NBP1-97657JF549
Janelia Fluor 646 NBP1-97657JF646
PE NBP1-97657PE
PE/Atto594 NBP1-97657PEATT594
PE/Cy5.5 NBP1-97657PECY55
PE/Cy7 NBP1-97657PECY7
PerCP NBP1-97657PCP

Additional LAG-3 Products

Bioinformatics Tool for LAG-3 Antibody (NBP1-97657)

Discover related pathways, diseases and genes to LAG-3 Antibody (NBP1-97657). Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
Visit Tool

Diseases for LAG-3 Antibody (NBP1-97657)

Discover more about diseases related to LAG-3 Antibody (NBP1-97657).
 

Pathways for LAG-3 Antibody (NBP1-97657)

View related products by pathway.

PTMs for LAG-3 Antibody (NBP1-97657)

Learn more about PTMs related to LAG-3 Antibody (NBP1-97657).
 

Research Areas for LAG-3 Antibody (NBP1-97657)

Find related products by research area.

Blogs on LAG-3

There are no specific blogs for LAG-3, but you can read our latest blog posts.

Customers Who Bought This Also Bought

Contact Information

Download our Western Blot eHandbook

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Recent Reviews

4.5
5
1
4
1
3
0
2
0
1
0

Verified Customer
03/07/2020
Application:
Species: Human

Verified Customer
01/23/2018
Application: IHC-P
Species: Human

Bioinformatics

Gene Symbol LAG3